Since then, the use of angiotensin receptor–neprilysin inhibitors (ARNIs) in HF with reduced LVEF and SGLT2 inhibitors in both HF with reduced and preserved LVEF have been introduced.1 The gene discussed is SLC5A2; the disease is hydrops fetalis.